

Candida Vitale

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3637216/publications.pdf>

Version: 2024-02-01

94
papers

1,330
citations

361413

20
h-index

395702

33
g-index

95
all docs

95
docs citations

95
times ranked

2429
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	5
2	How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	1.3	3
3	Old and New Drugs for Chronic Lymphocytic Leukemia: Lights and Shadows of Real-World Evidence. <i>Journal of Clinical Medicine</i> , 2022, 11, 2076.	2.4	6
4	Relative dose intensity of obinutuzumab-chlorambucil in chronic lymphocytic leukemia: a multicenter Italian study. <i>Blood Advances</i> , 2022, 6, 3875-3878.	5.2	2
5	Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL). <i>Leukemia</i> , 2021, 35, 737-746.	7.2	61
6	Real Life Use of Bendamustine in Elderly Patients with Lymphoid Neoplasia. <i>Journal of Personalized Medicine</i> , 2021, 11, 249.	2.5	6
7	B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2021, 137, 2267-2271.	1.4	10
8	Targeting HIF-1 β Regulatory Pathways as a Strategy to Hamper Tumor-Microenvironment Interactions in CLL. <i>Cancers</i> , 2021, 13, 2883.	3.7	12
9	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. <i>Blood</i> , 2021, 137, 3507-3517.	1.4	30
10	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	3.7	16
11	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 3856.	3.7	12
12	CD200 Baseline Serum Levels Predict Prognosis of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2021, 13, 4239.	3.7	1
13	Do age, fitness and concomitant medications influence management and outcomes of CLL patients treated with ibrutinib?. <i>Blood Advances</i> , 2021, , .	5.2	14
14	COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study. <i>Leukemia</i> , 2021, 35, 3444-3454.	7.2	57
15	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021, 138, 2635-2635.	1.4	1
16	Targeted Treatment of Chronic Lymphocytic Leukemia: Clinical Utility of Acalabrutinib. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 5507-5519.	2.0	1
17	Ofatumumab is safe and effective as front-line treatment in older patients with chronic lymphocytic leukemia and severe co-morbidities, including other malignancies. <i>Journal of Geriatric Oncology</i> , 2020, 11, 19-23.	1.0	2
18	HIF-1 β is over-expressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39

#	ARTICLE	IF	CITATIONS
19	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. <i>Expert Review of Hematology</i> , 2020, 13, 885-894.	2.2	2
20	Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib+rituximab. <i>Blood Cancer Journal</i> , 2020, 10, 92.	6.2	7
21	Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2020, 11, 594556.	4.8	39
22	CLL-131: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S222.	0.4	0
23	CLL-220: Modulation of Phenotypic and Functional Features of Immune Cells in Chronic Lymphocytic Leukemia Patients Treated with Ibrutinib. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, S224-S225.	0.4	0
24	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	4.8	45
25	CAR T-Cell Therapy for B-Cell non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Clinical Trials and Real-World Experiences. <i>Frontiers in Oncology</i> , 2020, 10, 849.	2.8	62
26	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
27	Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy. <i>Cancers</i> , 2020, 12, 1773.	3.7	4
28	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. <i>Cancers</i> , 2020, 12, 282.	3.7	22
29	Efficacy and Safety of Front-Line Venetoclax and Rituximab (VenR) for the Treatment of Young Patients with Chronic Lymphocytic Leukemia and an Unfavorable Biologic Profile. Preliminary Results of the Gimema Study 'Veritas'. <i>Blood</i> , 2020, 136, 47-49.	1.4	1
30	Retrospective Real-Life Comparison of Obinutuzumab Plus Chlorambucil Versus Ibrutinib in Previously Untreated and Unfit Patients with Chronic Lymphocytic Leukemia without TP53 Disruptions. Interim Results from the Italian CLL Campus. <i>Blood</i> , 2020, 136, 30-31.	1.4	0
31	Worldwide Examination of Patients with CLL Hospitalized for COVID-19. <i>Blood</i> , 2020, 136, 45-49.	1.4	2
32	Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?. <i>Blood</i> , 2020, 136, 54-55.	1.4	2
33	Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax. <i>Blood</i> , 2020, 136, 25-26.	1.4	3
34	A scoring system to predict the risk of atrial fibrillation in chronic lymphocytic leukemia. <i>Hematological Oncology</i> , 2019, 37, 508-512.	1.7	13
35	Elevated Lactate Dehydrogenase Has Prognostic Relevance in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Cancers</i> , 2019, 11, 896.	3.7	16
36	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S278-S279.	0.4	0

#	ARTICLE	IF	CITATIONS
37	CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. <i>Leukemia Research</i> , 2019, 83, 106169.	0.8	8
38	Lenalidomide can be safely combined with chlorambucil and rituximab in older patients with chronic lymphocytic leukemia. <i>Haematologica</i> , 2019, 104, 9-12.	3.5	3
39	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2019, 134, 3031-3031.	1.4	2
40	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
41	Pre-Existing and Treatment-Emergent Autoimmune Cytopenias in Patients with Chronic Lymphocytic Leukemia Treated with Targeted Drugs. <i>Blood</i> , 2019, 134, 3044-3044.	1.4	0
42	Abstract 2072: Selinexor in combination with chemotherapy or idelalisib elicits a synergistic cytotoxic effect in primary CLL cells. , 2019, , .		0
43	CD200 included in a 4â€marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2018, 36, 543-546.	1.7	21
44	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	1.4	40
45	External validation of the accuracy of â€CLLflow scoreâ€™. <i>Journal of Investigative Medicine</i> , 2018, 66, e6-e6.	1.6	4
46	LDH as Predictive Parameter in Treatment-Naïve Patients Affected by Chronic Lymphocytic Leukemia with Trisomy 12. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S213.	0.4	0
47	Regulation of HIF-1 Î± in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S214.	0.4	0
48	A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. <i>Blood</i> , 2018, 132, 3118-3118.	1.4	6
49	Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2018, 132, 4412-4412.	1.4	2
50	Magic pills: new oral drugs to treat chronic lymphocytic leukemia. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 411-425.	1.8	9
51	Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia. <i>European Journal of Haematology</i> , 2017, 99, 306-314.	2.2	12
52	Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies. <i>Journal of Immunology Research</i> , 2017, 2017, 1-13.	2.2	29
53	Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 3274-3288.	1.8	13
54	Acute promyelocytic leukemia presented as a relapse of acute myeloid leukemia. <i>American Journal of Hematology</i> , 2016, 91, E274-6.	4.1	2

#	ARTICLE	IF	CITATIONS
55	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2016, 101, e254-e258.	3.5	40
56	The CXCR4 Downstream Signaling Pathways in Chronic Lymphocytic Leukemia: a Target to Reverse Microenvironment Protection. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S42.	0.4	0
57	Update on Efficacy and Tolerability of Ofatumumab as Front-Line Treatment for Patients with CLL that are Elderly and Have Severe Co-Morbidities and/or Other Malignancies. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, S41.	0.4	0
58	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1077-1089.	1.8	13
59	Richter Syndrome in Chronic Lymphocytic Leukemia. <i>Current Hematologic Malignancy Reports</i> , 2016, 11, 43-51.	2.3	15
60	Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia. <i>Annals of Oncology</i> , 2016, 27, 1100-1106.	1.2	54
61	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016, 22, 2359-2367.	7.0	28
62	Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study. <i>Blood</i> , 2016, 128, 2038-2038.	1.4	3
63	LDH Levels Predict Progression-Free Survival in Treatment-Naïve Patients with Trisomy 12 Chronic Lymphocytic Leukemia. <i>Blood</i> , 2016, 128, 3211-3211.	1.4	2
64	HIF-1 α Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target. <i>Blood</i> , 2016, 128, 305-305.	1.4	0
65	Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance. <i>Blood</i> , 2016, 128, 3210-3210.	1.4	0
66	Bleeding Diathesis Associated with Acquired von Willebrand Syndrome in Three Patients with Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S201.	0.4	0
67	t(9;22) as secondary alteration in core-binding factor <i>de novo</i> acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, E211-2.	4.1	6
68	Anergic bone marrow V β 9V γ 2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. <i>Oncimmunology</i> , 2015, 4, e1047580.	4.6	58
69	Front-line Treatment with Ofatumumab in Elderly Unfit Patients with CLL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S26.	0.4	0
70	Other cancers in long-term survivor patients with chronic lymphocytic leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S26-S27.	0.4	0
71	Bleeding diathesis associated with acquired von Willebrand Syndrome in three patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 3452-3454.	1.3	9
72	The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. <i>Leukemia</i> , 2015, 29, 356-368.	7.2	33

#	ARTICLE	IF	CITATIONS
73	A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 1878-1880.	1.3	4
74	Front-Line Treatment with Ofatumumab for Older Unfit Patients with Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5292-5292.	1.4	2
75	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. <i>Oncotarget</i> , 2015, 6, 29833-29846.	1.8	33
76	The Hypoxia-Inducible Factor-1alpha Is Constitutively Upregulated in TP53 Disrupted CLL Cells: A Potential Target to Overcome Fludarabine Resistance. <i>Blood</i> , 2015, 126, 2925-2925.	1.4	0
77	IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2015, 126, 4136-4136.	1.4	0
78	Correlation Between Clinical Responses and Immune Characteristics in Patients with Relapsed CLL Treated with Ofatumumab and Lenalidomide. <i>Blood</i> , 2015, 126, 1748-1748.	1.4	0
79	The Mevalonate Metabolic Pathway and the CXCL12/CXCR4 Axis Reciprocally Interact and Are Implicated in Fludarabine Resistance of Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2014, 124, 833-833.	1.4	0
80	Early Results of a Phase II Study of Ofatumumab As Front-Line Treatment in Elderly, Unfit Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2014, 124, 5656-5656.	1.4	1
81	Regulation Of CLL Growth and Trafficking By The Enzymatic Functions Of CD38: Implications For Therapeutic Targeting. <i>Blood</i> , 2013, 122, 4112-4112.	1.4	0
82	Dysfunctional V β 9V δ 2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012, 120, 3271-3279.	1.4	51
83	Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2898-2898.	1.4	0
84	The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012, 120, 3881-3881.	1.4	0
85	Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA). <i>Blood</i> , 2012, 120, 3878-3878.	1.4	0
86	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental pro-survival signals than mutated CLL B cells. <i>Leukemia</i> , 2011, 25, 828-837.	7.2	61
87	V β 9V δ 2 T cell-based immunotherapy in hematological malignancies: from bench to bedside. <i>Cellular and Molecular Life Sciences</i> , 2011, 68, 2419-2432.	5.4	35
88	The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells. <i>Blood</i> , 2011, 118, 735-735.	1.4	0
89	Identification by Serological Proteome Analysis (SERPA) of Tumor-Associated Antigens Eliciting Antibody Responses In Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2010, 116, 917-917.	1.4	0
90	The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. <i>Blood</i> , 2010, 116, 3602-3602.	1.4	0

#	ARTICLE	IF	CITATIONS
91	IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals. <i>Blood</i> , 2010, 116, 2431-2431.	1.4	0
92	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. <i>Experimental Hematology</i> , 2009, 37, 728-738.	0.4	10
93	Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis.. <i>Blood</i> , 2009, 114, 2333-2333.	1.4	12
94	Case Report: Sequential Development of Three Mature Lymphoid Neoplasms in a Single Patient: Clonal Relationship and Molecular Insights. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	3